Unaudited financial results for the quarter ended September 30, 2026

NOVYRA CIN NO. :- L21001GJ1987PLC171085 PHARMACHEM LIMITED GST NO : 24AAACE6640F1Z0 November 02, 2026 The General Manager-Listing Corporate Relationship Department BSE Limited, Ground Floor, P.J. Towers, Dalal Street, Mumbai-400001 Scrip Code: - 519353 Dear Sir/Madam, Sub: Outcome of the meeting of the Board of Directors held on November 02, 2026 Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015 Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held on today ie. Monday, November 02, 2026 at the Registered Office of the Company inter-alia has, considered and approved the following; - 1. Un-Audited Financial Results of the Company for the Quarter and Half Year ended September 30, 2026, along with Auditors’ Limited Reports, in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations. 2. Reviewed the business of the company. The Board Meeting commenced at 4:30 P.M. and concluded at 5:15 P.M. You are requested to take the above information on records and disseminate the same on your respective websites. Thanking you, Yours faithfully, For, Novyra Pharmachem Limited ( formerly known as Bansisons Tea Industries Ltd ) For, Novyra Pharmachem Limited froit . el Y Director/Autho. Signatory Anilkumar Mohanbhai Amreliya Director DIN : 11339148 & novyrapharmachemlimited@gmail.com Q www.novyrapharmachemitd.com tr[]» +91 92654 53481 R S No. 432, T P Scheme No. 3, F P No. 89/A, City Survey No. 3763, Plot No. C, Palky Plot No. A, Ground Floor, Back Side, Pavthawala Compound, B/h Zenith Mill, Vasta Devdi Road, Surat- 395004, Gujarat, India NOVYRA PHARMACHEM LIMITED R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004 CIN : L21001GJ1987PLC171085 Statement of unaudited Assets and lial ties as on September 30th, 2026 ASSETS [Non-current assets [Property, Plant and Equipment Capital work-in-progress <) investment Property d) Goodwill [5) [Other Intangible assets [intangible assets under development [Biological Assets other than bearer plants ) [investments accounted for using equity method i) Financial Assets [0 Investments (i)} | Trade receivables (iid)] Loans Receivable Gv) Security Deposits i) | Deferred tax assets (net) 1) Other non-current assets Total Non-current assets| 117.76 74.09 2 [Current assets a) [lnventories 827 b) Financial Assets 0] Investments ) Trade receivables 157.45] 108} [ [Cash and cash cquivalents 2328 14.72] V)l Bank balances other than Cash and cash equivalents (2] Short Term Loans & Advances 0.08] 2437 ) Others [Current Tax Assets (Neh ) Other current assets 14.86] 1162 |Non-current assets classified as held for sale [Regulatory deferral account debit balances and related deferred tax assets Total Current Assets| 203.94 71.79 [EQUITY & LIABILITIES: Equity [Equity Share capital 633.00 630.00 [Other Equity G76.11) (570.79) “Total Equity| 56.89 59.21 |L iabilities Non-Current Liabilities [Financial Liabilities Long Term Borrowings Trade payables [Other financial liabilities (other than those specified in item (b). © be specified) [Provisions [Deferred tax liabilities (Net) [Deferred government grants (non current) [Other non-current liabilities |Current liabilities Financial Liabilities (i)]Short Term Borrowings Gii)| Trade payables [Total Outstanding Dues of creditors micro and small enterprise Total Outstanding Dues of creditors other than micro and small enterprise 261.63] 86.67 G| Other financial liabilities 0.19] 5 a)|Provisions 2.99] - )| Income/Current Tax Liabilities (Net) ©)fOther current liabilities Total Current Liabilities| 264.81 86.67 For, NOVYRA PHARMACHEM LIMITED For, Novyra Pharmachem Limited it Pravel 4 Director/Autho. Siflgato? Anilkumar Mohanbhai Amreliy Date :- 02-11-2026 Director DIN: 11339148 NOVYRA PHARMACHEM LIMITED R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India, 395004 CIN: L21001GJ1987PLC171085 Statement of unaudited Standalone Financial Results for the Quarter ended September 30, 2026 (R T akhis) For The Year Quarter Ended Half Year Ended Ended 30/092026 30/06/2026 30/09/2024 30/09/2026 30/09/ 317032026 A Date of 5t reporting period. 0170772026 9] 2026 OL07/2025 OL/O42026 01/04/2025 01042025 orting period 30/092026 30/06/2026 30/09/2025 30/09/2026 30/09202% 31/03/2026 results are audited or unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Audited [Revenue From Operations (&) Revenue From Operations (b) Other Income 3.70 - 3.31 3.70} 631 631 [Total Revenue from operations (nef) 2678 17261 331] _ 599.39 631 1675 Expenditure (@) Cost of materials consumed B - - - ] ] [(b) Purchases of stock-in-trade 41407 18913 60313 ] (e) Changes in inventories of finished goods, work-in-progress and stock-in-trade os4| 1781 - (®.27) : A (@) Emplovee benefit expense 24 060, 146) 302} 287 15,06} (e) Finance Costs - - -l -] - B () Depreciation and amortisation expense 030 030 073 0560) 143 2.59) () Other Expenses 383 238 1.03} 621 2.67] 536.17] [ Total_expenses 430.10] 174.60} 3.21) 604.70| 6.98] 554.13} Profit (loss) Before exceptional & Extraordinary items and Tax @3.32)| (1.99) 0.10 31| ©.67) (837.38) [Exceptional floms s . Profit (loss) from ordinary activities before tax 332) (099)] 0.10 JCED) 067 G3738) [Tax Expenses - Current Tax 3 [(less): MAT Credit - 5 ’ - ] ’ [Current Tax Expense Relating (o Prior years S s - - ] ] Deoferred Tax (Asscts) lbiltlcs - . [Profit (loss) from ordinary activities 3.32) 1.99)| 0.10 3D ©67)| (537.38)] Other Comprehensive Income (OCI) B B items that will not be reclassified to profitor loss 5 B ] ] ] ] e T e T TS AT ST IO e TECTaSSTITesr o promror = - . . . . Itcms that will be reclassified to profi or loss : - . ] ] ] Income tax relating to items that will be reclassified to profit or loss B - ] ] . ’ Total Prafit After Other Comprehiensive Income 332), 1.99)| 0.10] (31 ©.67)| (537.38) Profit/(Loss) From Discountinuing Operation Before Tax - - | Tax Expenses of Discontinuing Operations - - ] R [Net Proffirom( DiLscoountwinu)ing Opraion After Tax B H E - : E Profit(Loss) For Period Before Minority Interest - - R R B [Share OF Profit / Loss Associates - - B | [ProfitOf/ MLinoorsitsy Interset = - - - [Net Profit (+)/ Loss (-) For the Period (3.33) (1.99)] 0.10 (531)] ©67)] (537.38) [Details of equity share capital S B | [Paid-up cquity share capital 633,00} 633.00] 630,00} 633,00} 630,00} 63300} [Face value cofq uity share capital (per share) 10.00) 10.00) 10.00) 10.00] 10.00 1001 Reserve Excluding Revaluation Reserves As Par Balance sheet Of previous Year R R R Earnings per share (EPS) ] [Basic earnings per share from countinuiAnngd Discountinuing operations (0.05)] 0.03)] 0.00] (0.08)] 0.0 (849 [Diluted earnings per share from countinuing And Discountinuing operations 005) ©03)] 0.00 (0.08)] 001 ICED| Notes:- [The above said finanical resulls were reviewed by the Audit Committee and then approved by the Board of Dircctors at their respective Meetings held on 11th October , 2025. 2 | The Statutory Auditors have carried out limited review of the Unaudited Results oft he Company for the Quarter ended 30/09/2025. These results have been prepared in accordance with the Indian Accounting Standard (referred o as "nd AS") 34 - Interim Financial Reporting proscribed under Scetion 133 of the |Companics Act, 2013 read with Companics (Indian Accounting Standards) Rules as amended from time to time. [The Company has 1o reportable business segment. Fence, scparate information for segment wise disclosure is given i accordance with the requirements of Ind AS (AS) 108 - Statement of Assets and Liabilities and cashflow statement as on 30th Scptember 2025 i cnclosed herowi [Showing first 8,000 characters — download PDF for full document]